Incyte Corp. [INCY] stock is trading at $60.53, down -0.10%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The INCY shares have gain 4.43% over the last week, with a monthly amount drifted -0.64%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 15, February 2024, Incyte to Present at Upcoming Investor Conference. In a post published today on Yahoo Finance, Incyte (Nasdaq:INCY) announced today that it will present at the Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 9:50 a.m. (EST) in Boston.
From an analyst’s perspective:
Incyte Corp. [NASDAQ: INCY] stock has seen the most recent analyst activity on February 23, 2024, when Jefferies initiated its Buy rating and assigned the stock a price target of $81. Previously, JMP Securities downgraded its rating to Mkt Perform on February 14, 2024. On December 13, 2023, upgrade upgraded it’s rating to Outperform but maintained its price target of $78 on the stock. Guggenheim upgraded its rating to a Buy but stick to its price target of $86 on December 04, 2023. Goldman downgraded its rating to a Neutral and reduced its price target to $65 on November 21, 2023. Citigroup started tracking with a Buy rating for this stock on July 25, 2023, and assigned it a price target of $82. In a note dated May 04, 2023, BofA Securities downgraded an Neutral rating on this stock but restated the target price of $84.
Incyte Corp. [INCY] stock has fluctuated between $50.27 and $78.02 over the past year. Currently, Wall Street analysts expect the stock to reach $89.5 within the next 12 months. Incyte Corp. [NASDAQ: INCY] shares were valued at $60.53 at the most recent close of the market. An investor can expect a potential return of 47.86% based on the average INCY price forecast.
Analyzing the INCY fundamentals
Incyte Corp. [NASDAQ:INCY] reported sales of 3.70B for the trailing twelve months, which represents a growth of 9.35%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 59.94 points at the first support level, and at 59.35 for the second support level. However, for the 1st resistance point, the stock is sitting at 61.28, and for the 2nd resistance point, it is at 62.03.
Incyte Corp. [INCY] reported earnings per share of $1.06 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $1.16/share, meaning a difference of -$0.1 and a surprise factor of -8.60%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $1.1 per share as compared to estimates of $1.02 per share, a difference of $0.08 representing a surprise of 7.80%.
Ratios To Look Out For
For context, Incyte Corp.’s Current Ratio is 3.75. Also, the Quick Ratio is 3.69, while the Cash Ratio stands at 0.05. Considering the valuation of this stock, the price to sales ratio is 3.68, the price to book ratio is 2.62 and price to earnings (TTM) ratio is 22.89.
Transactions by insiders
Recent insider trading involved Stein Steven H, EVP & Chief Medical Officer, that happened on Jan 03 when 7365.0 shares were sold. EVP, GMAPPS, Iyengar Vijay K completed a deal on Jan 02 to sell 657.0 shares. Meanwhile, Principal Accounting Officer Tray Thomas sold 1067.0 shares on Dec 13.
